A mathematical model of bone remodeling dynamics for normal bone cell populations and myeloma bone disease.
BACKGROUND
Multiple myeloma is a hematologic malignancy associated with the development of a destructive osteolytic bone disease.


RESULTS
Mathematical models are developed for normal bone remodeling and for the dysregulated bone remodeling that occurs in myeloma bone disease. The models examine the critical signaling between osteoclasts (bone resorption) and osteoblasts (bone formation). The interactions of osteoclasts and osteoblasts are modeled as a system of differential equations for these cell populations, which exhibit stable oscillations in the normal case and unstable oscillations in the myeloma case. In the case of untreated myeloma, osteoclasts increase and osteoblasts decrease, with net bone loss as the tumor grows. The therapeutic effects of targeting both myeloma cells and cells of the bone marrow microenvironment on these dynamics are examined.


CONCLUSIONS
The current model accurately reflects myeloma bone disease and illustrates how treatment approaches may be investigated using such computational approaches.


METHODS
This article was reviewed by Ariosto Silva and Mark P. Little.
Ayati
Bruce P
BP
Department of Mathematics, University of Iowa, Iowa City, IA 52242, USA. ayati@math.uiowa.edu
Edwards
Claire M
CM
Webb
Glenn F
GF
Wikswo
John P
JP
D000818:Animals; D016723:Bone Remodeling / Q000502:physiology*; D006801:Humans; D008962:Models, Theoretical; D009101:Multiple Myeloma / Q000473:pathology*; D010010:Osteoclasts / Q000166:cytology*; D010011:Osteocytes / Q000166:cytology*
PLoS One. 2008 May 07;3(5):e2104
18461134
J Bone Miner Res. 2009 May;24(5):860-70
19063683
Br J Haematol. 1982 Dec;52(4):601-10
7138789
Eur J Haematol. 1998 Aug;61(2):128-34
9714526
Br J Haematol. 2006 Dec;135(5):688-92
17107351
J Clin Invest. 2003 Jun;111(11):1771-82
12782679
N Engl J Med. 1974 Nov 14;291(20):1041-6
4413338
J Cell Biochem. 1994 Jul;55(3):273-86
7962158
J Bone Miner Metab. 2005;23(1):1-7
15616887
Bone. 2004 Oct;35(4):918-28
15454099
J Clin Invest. 1991 Jul;88(1):62-6
2056131
Cancer. 1990 Jul 1;66(1):167-72
2354403
Am J Hematol. 2009 May;84(5):268-72
19296472
Clin Chem. 2001 Apr;47(4):686-93
11274019
Blood. 2008 Oct 1;112(7):2935-45
18535198
Bone. 2003 Aug;33(2):206-15
14499354
Eur J Cancer. 1998 Feb;34(2):246-51
9741328
Nature. 2008 Jul 10;454(7201):221-5
18548006
Conf Proc IEEE Eng Med Biol Soc. 2006;2006:3154-7
17947010
Br J Haematol. 2007 Nov;139(3):434-8
17910634
Endocrinology. 2005 Aug;146(8):3589-95
15860557
Cancer Res. 2001 Apr 1;61(7):3071-6
11306489
Cancer Res. 2002 Sep 1;62(17):4996-5000
12208752
Biochem Biophys Res Commun. 2005 Jul 22;333(1):200-5
15936724
J Bone Joint Surg Br. 1989 Mar;71(2):288-90
2925748
Clin Lymphoma Myeloma. 2007 Nov;7(9):587-9
18186967
Eur J Haematol. 1992 Oct;49(4):192-8
1464362
Am J Hematol. 2009 Jan;84(1):6-14
18980173
Comput Methods Biomech Biomed Engin. 2009 Jun;12(3):341-52
19089785
J Theor Biol. 2004 Aug 7;229(3):293-309
15234198
Leuk Res. 2001 Oct;25(10):901-7
11532524
Biomech Model Mechanobiol. 2005 Nov;4(2-3):147-67
15942795
Biophys Chem. 2007 May;127(3):194-212
17321664
Bone. 2008 Aug;43(2):249-63
18514606
J Biomed Mater Res. 2002 May;60(2):292-9
11857436
Ann N Y Acad Sci. 2006 Apr;1068:557-9
16831951